A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model

In the present study, the breast cancer patient-derived orthotopic xenograft (PDOX) model was used to identify an effective drug for a highly aggressive triple negative breast cancer (TNBC). The TNBC tumor from a patient was implanted in the right 4th inguinal mammary fat pad of nude mice to establi...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-05, Vol.40 (5), p.2481-2485
Main Authors: Lim, Hye In, Yamamoto, Jun, Inubushi, Sachiko, Nishino, Hiroto, Tashiro, Yoshihiko, Sugisawa, Norihiko, Han, Quinhong, Sun, Y U, Choi, Hee Jun, Nam, Seok Jin, Kim, Moon Bo, Lee, Ji Sun, Hozumi, Chihiro, Bouvet, Michael, Singh, Shree Ram, Hoffman, Robert M
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - administration & dosage
Breast cancer
Cell Line, Tumor
Disease Models, Animal
Disease Progression
Furans - administration & dosage
Histocytochemistry
Humans
Ketones - administration & dosage
Mice
Neoplasm Metastasis
Regrowth
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - etiology
Triple Negative Breast Neoplasms - pathology
Tumor Burden - drug effects
Tumors
Xenograft Model Antitumor Assays
Xenografts
Xenotransplantation
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the present study, the breast cancer patient-derived orthotopic xenograft (PDOX) model was used to identify an effective drug for a highly aggressive triple negative breast cancer (TNBC). The TNBC tumor from a patient was implanted in the right 4th inguinal mammary fat pad of nude mice to establish a PDOX model. Three weeks later, 19 mice were randomized into the untreated-control group (n=10) and the eribulin treatment group (n=9, eribulin, 0.3 mg/kg, i.p., day 1). On day 8, eribulin significantly inhibited tumor volume compared to the control group (p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14218